Investigating how lung cells can break down scar tissue in pulmonary fibrosis.
Therapeutic ECM Resorption in Cellular Systems and Precision Cut Lung Slices.
This study is looking at ways to help lung cells break down scar tissue in people with idiopathic pulmonary fibrosis (IPF), with the hope of finding new treatments to improve lung function.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10745723 on NIH RePORTER |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a condition where lung tissue is progressively replaced by scar tissue, hindering gas exchange. The study aims to understand the conditions that allow lung cells, particularly fibroblasts, to resorb this scar tissue. By developing model systems using primary lung fibroblasts and precision cut lung slices, the researchers will explore how to stimulate these cells to degrade collagen-rich scars. The ultimate goal is to identify biological pathways and potential therapies that could enhance the natural resorption of scar tissue in patients with IPF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are experiencing progressive lung scarring.
Not a fit: Patients with other forms of lung disease or those without significant lung scarring may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help restore lung function by promoting the breakdown of scar tissue in patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in understanding the resorption of fibrotic tissue in other contexts, but this specific approach in IPF is relatively novel.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Tschumperlin, Daniel J. — Mayo Clinic Rochester
- Study coordinator: Tschumperlin, Daniel J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.